Cost Of New Drug Development Pushed To $2.6 Bil. By High Failure Rate – Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The Tufts Centers for the Study of Drug Development updates its often-quoted drug development cost benchmark in a study released Nov. 18.
You may also be interested in...
Latest R&D Spending Benchmark Study Puts Cancer Drug Costs At $648M
Estimate in JAMA paper is significantly lower than often-cited $2.6bn in research and development costs projected in a 2014 study by Tufts Center for the Study of Drug Development.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.